Imatinib Mesylate in Treating Patients With Recurrent Small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have
recurrent small cell lung cancer. Imatinib mesylate may stop the growth of cancer cells by
blocking the enzymes necessary for cancer cell growth.